Molecular biology of breast cancer metastasis - Inflammatory breast cancer: clinical syndrome and molecular determinants

被引:161
作者
Kleer, CG
van Golen, KL
Merajver, SD
机构
[1] Univ Michigan, Med Ctr, Dept Pathol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Med Ctr, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
来源
BREAST CANCER RESEARCH | 2000年 / 2卷 / 06期
关键词
inflammatory breast cancer; insulin-like growth factor-binding proteins; molecular genetics; RhoC GTPase;
D O I
10.1186/bcr89
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inflammatory breast cancer (IBC) is an aggressive form of locally advanced breast cancer (LABC) that effects approximately 5% of women with breast cancer annually in the USA. It is a clinically and pathologically distinct form of LABC that is particularly fast growing, invasive, and angiogenic. Nearly all women have lymph node involvement at the time of diagnosis, and approximately 36% have gross distant metastases. Despite recent advances in multimodality treatments, the prognosis of patients with IBC is poor, with a median disease-free survival of less than 2.5 years. Recent work on the genetic determinants that underlie the IBC phenotype has led to the identification of genes that are involved in the development and progression of this disease. This work has been aided by the establishment of primary human cell lines and animal models. These advances suggest novel targets for future interventions in the diagnosis and treatment of IBC.
引用
收藏
页码:423 / 429
页数:7
相关论文
共 53 条
[1]   PROGNOSIS FOLLOWING SALVAGE MASTECTOMY FOR RECURRENCE IN THE BREAST AFTER CONSERVATIVE SURGERY AND RADIATION-THERAPY FOR EARLY-STAGE BREAST-CANCER [J].
ABNER, AL ;
RECHT, A ;
EBERLEIN, T ;
COME, S ;
SHULMAN, L ;
HAYES, D ;
CONNOLLY, JL ;
SCHNITT, SJ ;
SILVER, B ;
HARRIS, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :44-48
[2]   Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) [J].
Achen, MG ;
Jeltsch, M ;
Kukk, E ;
Mäkinen, T ;
Vitali, A ;
Wilks, AF ;
Alitalo, K ;
Stacker, SA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :548-553
[3]  
Alpaugh ML, 1999, CANCER RES, V59, P5079
[4]  
BACLESSE F, 1949, AM J ROENTGENOL, V62, P311
[5]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[6]  
BLONDAL JA, 1994, SEMIN CANCER BIOL, V5, P177
[7]  
BRUCKMAN JE, 1979, CANCER-AM CANCER SOC, V43, P985, DOI 10.1002/1097-0142(197903)43:3<985::AID-CNCR2820430330>3.0.CO
[8]  
2-1
[9]   Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas [J].
Burger, AM ;
Zhang, X ;
Li, H ;
Ostrowski, JL ;
Beatty, B ;
Venanzoni, M ;
Papas, T ;
Seth, A .
ONCOGENE, 1998, 16 (19) :2459-2467
[10]   Role of insulin-like growth factor binding proteins in controlling IGF actions [J].
Clemmons, DR .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 1998, 140 (1-2) :19-24